Alpha Omega Wealth Management LLC boosted its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 125.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,412 shares of the medical research company’s stock after buying an additional 787 shares during the period. Alpha Omega Wealth Management LLC’s holdings in Amgen were worth $263,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also bought and sold shares of the stock. Baker Ellis Asset Management LLC purchased a new position in Amgen in the third quarter valued at about $108,000. Phocas Financial Corp. purchased a new position in Amgen in the second quarter valued at about $110,000. Jackson Grant Investment Advisers Inc. grew its stake in Amgen by 0.8% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock valued at $110,000 after purchasing an additional 5 shares in the last quarter. Omnia Family Wealth LLC grew its stake in Amgen by 25.3% in the second quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock valued at $125,000 after purchasing an additional 147 shares in the last quarter. Finally, Grove Bank & Trust grew its stake in Amgen by 87.4% in the second quarter. Grove Bank & Trust now owns 731 shares of the medical research company’s stock valued at $126,000 after purchasing an additional 341 shares in the last quarter. 78.46% of the stock is currently owned by hedge funds and other institutional investors.
In related news, Director Carbonnel Francois De sold 4,000 shares of the business’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total transaction of $694,440.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $171.58, for a total value of $261,659.50. Following the transaction, the executive vice president now directly owns 57,631 shares of the company’s stock, valued at approximately $9,888,326.98. The disclosure for this sale can be found here. In the last quarter, insiders have sold 7,050 shares of company stock valued at $1,225,765. 0.19% of the stock is currently owned by corporate insiders.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.11 by $0.16. The company had revenue of $5.77 billion during the quarter, compared to the consensus estimate of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The firm’s revenue was down .7% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.02 EPS. research analysts expect that Amgen, Inc. will post 12.71 earnings per share for the current year.
Amgen declared that its board has authorized a stock repurchase program on Wednesday, October 25th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to reacquire shares of its stock through open market purchases. Shares buyback programs are often a sign that the company’s board believes its shares are undervalued.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be paid a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a dividend yield of 2.90%. The ex-dividend date is Wednesday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $1.15. Amgen’s dividend payout ratio is 41.55%.
A number of research analysts have commented on the company. Vetr downgraded Amgen from a “buy” rating to a “hold” rating and set a $184.25 target price on the stock. in a research note on Wednesday, January 3rd. Oppenheimer set a $205.00 target price on Amgen and gave the company a “buy” rating in a research note on Friday, January 5th. Piper Jaffray Companies restated a “buy” rating on shares of Amgen in a research note on Tuesday, January 2nd. BMO Capital Markets restated a “hold” rating and issued a $199.00 target price on shares of Amgen in a research note on Monday, September 25th. Finally, Credit Suisse Group restated a “neutral” rating and issued a $186.00 target price (up previously from $177.00) on shares of Amgen in a research note on Friday, September 29th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $190.15.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.